Video

Matthew Galsky Gives an Overview of Bladder Cancer

Author(s):

Dr. Matthew Galsky

Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.

Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.

Galsky gives an overview of each bladder cancer type, starting with non-muscle invasive bladder cancer, and talks about treatment options and likelihood of cure or recurrence.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content
Illustration of bladder.
April 29th 2025

TAR-200 Shows High Response Rates in Bladder Cancer Subset

Kyle Doherty
TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the phase 2b SunRISe-1 study.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Illustration of a bladder.
April 28th 2025

TAR-200 Achieves High DFS and Bladder Preservation Rates in Bladder Cancer Subgroups

Ryan Scott
TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Image of bladder.
April 17th 2025

Antibody-Drug Conjugates Changed the Standard of Care in Bladder Cancer

Alex Biese
Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent treatments.
Illustration of bladder.
April 16th 2025

FDA sBLA Submitted for Anktiva Plus BCG in Papillary Bladder Cancer

Alex Biese
A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.